Samsung Biologics signs additional development and manufacturing agreement with STCube
SONGDO, South Korea, July 11, 2020 /PRNewswire/ — Samsung Biologics (207940.KS) has further expanded its partnership with STCube through an additional development and manufacturing service agreement of STM418, an anti-PD1 immuno-oncology candidate. STM418 received much attention from the…
Comments Off on Samsung Biologics signs additional development and manufacturing agreement with STCube